Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China
Eisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced that the Biologics License Application (BLA) for...
Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics
Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) has entered a multi-year strategic agreement with Iambic Therapeutics,...
Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China
Hemony Pharmaceutical Co., Ltd. has entered a strategic partnership with Insud Pharma, a leading Spanish...
Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development
Overseas Pharmaceuticals Ltd (OPL), a China-based specialty pharmaceutical company, has entered a product development and...
Xianju Pharmaceutical and Adamerck Grant Aspen China Rights to Aomeikesong Neuromuscular Reversal Agent
Zhejiang Xianju Pharmaceutical Co., Ltd. (SHE: 002332) and Hangzhou Adamerck Pharmlabs Inc. have entered a...
Zhendong Pharmaceutical Secures China Promotion Rights to Ferring’s Sodium Picosulfate
Shanxi Zhendong Pharmaceutical Co., Ltd. (SHE: 300158) has entered a strategic partnership with Ferring Pharmaceuticals...
GenAssist Therapeutic Partners with Indian DART Foundation on Duchenne Muscular Dystrophy Base Editing
Suzhou GenAssist Therapeutic Co., Ltd. has signed a Memorandum of Understanding (MoU) with India’s Dystrophy...
Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million
Foresee Pharmaceuticals has entered an exclusive global licensing agreement with Primevera Therapeutics, a German biotech...
Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market
Formosa Pharmaceuticals, Inc. (TPE: 6838) has entered an exclusive licensing agreement with Samil Pharmaceuticals Co.,...
Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal
Nanjing Hanxin Pharmaceutical Technology Co., Ltd. has entered a licensing agreement with Amphastar Pharmaceuticals, Inc....
Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) has entered a strategic licensing agreement with...
Henlius Biotech Secures Global Rights to U-mab’s IL-1RAP Antibody in Licensing Deal
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a licensing agreement with U-mab Biopharma, acquiring exclusive...
Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has entered a strategic licensing agreement with Qilu...
Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med
Kintor Pharmaceutical Limited (HKG: 9939) has entered an exclusive marketing service agreement with Beijing Dekai...
Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage
Huadong Medicine Co., Ltd (SHE: 000963) announced a key milestone in its strategic collaboration with...
Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology
Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) has entered a strategic partnership with Shanghai RAAS...
Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
Delonix Bioworks announced that DX-104, its Group B meningococcal (MenB) vaccine candidate, has received clinical...
Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market
Peijia Medical Ltd (HKG: 9996) announced it has submitted CE mark registration under the European...
Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego
Novartis AG (NYSE: NVS) held a groundbreaking ceremony for a state-of-the-art global biomedical research center...
Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer
Sino Biopharmaceutical Ltd (HKG: 1177) announced completion of patient enrollment for the registrational Phase III...